https://carb-x.org/carb-x-news/novo-nordisk-foundation-partners-with-carb-x/
(HELLERUP and BOSTON: January 9, 2024) – The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this space.
(黑勒鲁普和波士顿：2024 年 1 月 9 日）–诺和诺德基金会将投入高达 2500 万美元，用于支持预防、诊断和治疗最危险的耐药细菌感染的创新工具的早期开发。这笔为期三年的赠款将提供给抗生素耐药菌生物制药加速器（CARB-X），该加速器是该领域全球领先的非营利性公私合作机构。
Antimicrobials, including antibiotics, are the world’s primary defence against infections. But when the bacteria, viruses, fungi or parasites that cause those infections mutate and become resistant to existing treatments, simple infections can lead to severe illness or death.
包括抗生素在内的抗菌药物是世界上抵御感染的主要手段。但是，当引起这些感染的细菌、病毒、真菌或寄生虫发生变异并对现有治疗产生抗药性时，简单的感染就会导致严重的疾病或死亡。
Antimicrobial resistance (AMR) threatens to unravel societies and the global economic system by increasing the risks of performing routine medical procedures such as caesarean sections, hip replacements and chemotherapy, impairing our food chain, and diminishing productivity. The most comprehensive assessment of the burden of AMR to date found that drug-resistant bacterial infections alone caused an estimated 3,500 deaths every day in 2019, a number on the rise and already higher than both HIV/AIDS and malaria. According to the World Bank, in a high AMR-impact scenario, the world would lose 3.8 percent of its annual GDP by 2050, with an annual shortfall of $3.4 trillion by 2030.
抗菌药耐药性（AMR）增加了进行剖腹产、髋关节置换和化疗等常规医疗程序的风险，损害了我们的食物链，降低了生产力，因而有可能破坏社会和全球经济体系。迄今为止对 AMR 造成的负担进行的最全面评估发现，仅耐药细菌感染一项，在 2019 年估计每天就会造成 3500 人死亡，这一数字还在上升，已经高于艾滋病毒/艾滋病和疟疾。根据世界银行的数据，在 AMR 影响较大的情况下，到 2050 年，全球每年的 GDP 将损失 3.8%，到 2030 年，每年的缺口将达到 3.4 万亿美元。
A key part of the solution is the development of new vaccines, diagnostic tools, antibiotics, and other innovative interventions that can help prevent these infections, diagnose them quickly and accurately, and treat them effectively. Yet, most major pharmaceutical companies have exited the market and those left in the early development space tend to be academic spinouts and small companies in need of grants and guidance.
解决方案的一个关键部分是开发新型疫苗、诊断工具、抗生素和其他创新干预措施，以帮助预防这些感染、快速准确地诊断感染和有效治疗感染。然而，大多数大型制药公司已经退出市场，留在早期开发领域的往往是需要资助和指导的学术衍生公司和小公司。
CARB-X, a global non-profit partnership funded by four G7 governments and three of the world’s biggest foundations, is a leading provider of support to these product developers. The partnership, therefore, plays a crucial role in moving promising ideas for cutting-edge antibacterial products from basic research to clinical development and through Phase 1 clinical trials. Since 2016, CARB-X has funded 93 projects in 12 countries. Nineteen projects have advanced into or completed clinical trials; 12 remain active in clinical development, including late-stage clinical trials; and two diagnostic products have reached the market.
CARB-X 是由七国集团中的四国政府和世界上最大的三个基金会资助的全球非营利性合作伙伴关系，是为这些产品开发商提供支持的主要机构。因此，该合作伙伴关系在推动有前景的尖端抗菌产品创意从基础研究走向临床开发并通过一期临床试验方面发挥着至关重要的作用。自2016年以来，CARB-X已在12个国家资助了93个项目。19个项目已进入或完成临床试验；12个项目仍在积极进行临床开发，包括后期临床试验；两个诊断产品已进入市场。
“Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections,” says Peter Lawætz Andersen, Senior Vice President in Infectious Disease at the Foundation. “By partnering, we can help ensure that the best research gets translated into effective, scalable and affordable medical interventions that can help end this growing pandemic.”
“与 CARB-X 一样，诺和诺德基金会也致力于在抗击耐药感染的斗争中推动创新，”基金会传染病高级副总裁 Peter Lawætz Andersen 说。”通过合作，我们可以帮助确保将最好的研究成果转化为有效、可推广和负担得起的医疗干预措施，从而帮助结束这一日益严重的流行病。
“CARB-X is grateful for this generous contribution from the Novo Nordisk Foundation, a key ally in CARB-X’s mission,” says Kevin Outterson, Executive Director of CARB-X and Austin B. Fletcher Professor of Law at Boston University. “This new funding is a testament to our shared commitment to supporting the pioneering efforts of antibacterial product developers, mainly university spinoffs and small biotech companies, in advancing much-needed innovation to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections.”
“CARB-X执行董事、波士顿大学奥斯汀-弗莱彻法学教授凯文-奥特森（Kevin Outterson）表示：”诺和诺德基金会是CARB-X的重要盟友，CARB-X非常感谢诺和诺德基金会的慷慨捐助。”这笔新资金证明了我们共同的承诺，即支持抗菌产品开发商（主要是大学附属公司和小型生物技术公司）的开拓性努力，推动急需的创新，预防、诊断和治疗最危险的耐药细菌感染。
Battling a broken market 与破碎的市场作斗争
Despite the importance of antibiotics in modern medicine, only two new classes (types) have reached the market since 1962 and there are very few in clinical development. According to the World Health Organization, “the clinical pipeline and the recently approved antibacterial agents are insufficient to tackle the challenge of increasing emergence and the spread of AMR.”
尽管抗生素在现代医学中占有重要地位，但自 1962 年以来，只有两类（型）新抗生素进入市场，而且处于临床开发阶段的抗生素也寥寥无几。根据世界卫生组织的说法，”临床管线和最近批准的抗菌剂不足以应对 AMR 日益出现和蔓延的挑战”。
Private investments in innovative antibiotics are poor partly because doctors use them only when older and cheaper drugs fail. This is important to prolong their effectiveness, but it also limits their sales. This broken market has created a huge funding gap in antibacterial product development. A report for the European Commission has recently estimated that an additional global investment of USD 250 to 400 million from public and philanthropic sources is needed every year for the R&D of products that counter drug resistance, and that this investment should focus in the early phase of development, which is where CARB-X operates.
对创新抗生素的私人投资很少，部分原因是医生只有在较老和较便宜的药物失效时才会使用这些药物。这对延长抗生素的疗效非常重要，但同时也限制了抗生素的销售。这一破碎的市场造成了抗菌产品开发的巨大资金缺口。据欧盟委员会最近的一份报告估计，全球每年需要从公共和慈善来源额外投资 2.5 亿至 4 亿美元，用于抗药性产品的研发。
Novo Holdings – the Foundation’s wholly owned subsidiary – established the REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund in 2018 to address this early-stage funding gap. While continuing to support the existing portfolio, REPAIR has paused new investments due to the challenging market conditions, with the Foundation now supporting the critical early-stage pipeline via the philanthropic grant to CARB-X.
基金会的全资子公司诺和诺德控股公司（Novo Holdings）于 2018 年成立了 REPAIR（Replenishing and Enabling the Pipeline for Anti-Infective Resistance）影响力基金，以解决这一早期阶段的资金缺口。在继续支持现有投资组合的同时，REPAIR 因市场条件严峻而暂停了新的投资，基金会目前通过对 CARB-X 的慈善资助来支持关键的早期管线。
Developing cutting-edge products
开发尖端产品
The grant is also part of a broader commitment from the Foundation and Novo Holdings to fight drug resistance through the development of innovative products. The organisations are engaged in a range of activities from early development to advocating for payment models that can help rejuvenate the market for antimicrobials. The Foundation is also funding a major new initiative – the Novo Nordisk Foundation Initiative for Vaccines and Immunity – that will reduce the use of antibiotics and thus the spread of AMR by developing vaccines against respiratory infections.
这笔赠款也是基金会和诺和控股公司通过开发创新产品抗击耐药性这一更广泛承诺的一部分。这两家机构正在开展一系列活动，从早期开发到倡导有助于振兴抗菌药市场的支付模式。基金会还资助了一项重要的新倡议–诺和诺德基金会疫苗与免疫倡议，通过开发呼吸道感染疫苗，减少抗生素的使用，从而减少耐药性的传播。
With this grant, the Novo Nordisk Foundation joins major governments and foundations in supporting the work of CARB-X. Efforts are focused on the most dangerous bacteria which have been prioritized by the World Health Organization and the United States Centers for Disease Control and Prevention (CDC), the syndromes with the greatest morbidity and mortality across the world, and the performance characteristics that clinicians and patients need the most. Beyond non-dilutive funding, CARB-X provides grantees with scientific, clinical, regulatory, and business development guidance and access to tools that aim to accelerate product development.
有了这笔资助，诺和诺德基金会与主要政府和基金会一起支持 CARB-X 的工作。工作重点是世界卫生组织（WHO）和美国疾病控制与预防中心（CDC）优先考虑的最危险细菌、全球发病率和死亡率最高的综合症以及临床医生和患者最需要的性能特征。除了非稀释性资助外，CARB-X 还为受资助者提供科学、临床、监管和业务发展方面的指导，并提供旨在加速产品开发的工具。
Novo Nordisk Foundation Contact:
诺和诺德基金会联系人
Judith Vonberg, +45 4172 7925, jvo@novo.dk
Judith Vonberg，+45 4172 7925，jvo@novo.dk
CARB-X Contact: Genevieve Holmes, carbxpr@bu.edu
CARB-X 联系人：Genevieve Holmes，carbxpr@bu.edu
About the Novo Nordisk Foundation
关于诺和诺德基金会
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
诺和诺德基金会于 1924 年在丹麦成立，是一家以慈善为目标的企业基金会。基金会的愿景是改善人们的健康状况，促进社会和地球的可持续发展。基金会的使命是推动心脏代谢疾病和传染病预防和治疗领域的研究与创新，并推动知识和解决方案的发展，以支持社会的绿色转型。
www.novonordiskfonden.dk/en
About CARB-X 关于 CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. CARB-X supports innovative therapeutics, preventatives and rapid diagnostics. CARB-X is led by Boston University and funded by a consortium of governments and foundations. CARB-X funds only projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. https://carb-x.org/ | X (formerly Twitter) @CARB_X
CARB-X（抗耐药菌生物制药加速器）是一家全球性非营利合作机构，致力于支持早期抗菌研究和开发，以应对日益严重的耐药菌威胁。CARB-X 支持创新治疗、预防和快速诊断。CARB-X 由波士顿大学牵头，由政府和基金会联合资助。CARB-X 只资助针对美国疾病预防控制中心（CDC）抗生素耐药性威胁名单或世界卫生组织（WHO）公布的优先细菌病原体名单中重点列出的耐药细菌的项目，优先资助美国疾病预防控制中心（CDC）名单中严重或紧急病原体或世界卫生组织（WHO）名单中危重或高度病原体。 https://carb-x.org/ | X（前身为 Twitter） @CARB_X
CARB-X is supported by federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number 75A50122C00028, and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Education and Research (BMBF), the UK Global Antimicrobial Resistance Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC), the Bill & Melinda Gates Foundation, and the Novo Nordisk Foundation. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of any CARB-X funders.
CARB-X 得到了美国卫生与公众服务部（HHS）、战略准备与响应管理局、生物医学高级研究与发展局的联邦基金支持，协议编号为 75A50122C00028。CARB-X 得到了美国卫生与公众服务部 (HHS)、战略准备与响应管理局、生物医学高级研究与发展局的联邦基金的支持，协议编号为 75A50122C00028，还得到了惠康公司 (WT224842) 和德国联邦教育与研究部 (BMBF) 的奖励，以及英国政府卫生与社会保健部 (DHSC) 资助的英国全球抗菌药耐药性创新基金 (GAMRIF)、比尔及梅林达-盖茨基金会和诺和诺德基金会的支持。美国国家过敏与传染病研究所（NIAID）隶属于 HHS 的国家卫生研究院（NIH），通过提供产品开发的临床前服务套件，以实物服务的形式提供支持。本新闻稿内容仅由作者本人负责，不代表任何 CARB-X 资助方的官方观点。
About BARDA and NIAID 关于 BARDA 和 NIAID
The U.S. Department of Health and Human Services works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The Administration for Strategic Preparedness and Response (ASPR) leads the nation’s medical and public health preparedness for, response to and recovery from disasters and other public health emergencies. Within ASPR, the Biomedical Advanced Research and Development Authority (BARDA) invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products – needed to combat health security threats and is one of the leading public sector funders of advanced development of antimicrobial therapeutics and diagnostics.
美国卫生与公众服务部致力于提高和保护所有美国人的健康和福祉，提供有效的卫生和公众服务，促进医学、公共卫生和社会服务的进步。战略准备和反应管理局（ASPR）负责领导国家的医疗和公共卫生准备工作，应对灾害和其他公共卫生突发事件并从中恢复。在战略准备与反应管理局内，生物医学高级研究与发展局（BARDA）投资于创新、高级研发、采购和制造应对健康安全威胁所需的医疗对策–疫苗、药物、疗法、诊断工具和非药物产品，并且是抗菌疗法和诊断高级开发的主要公共部门资助者之一。
As part of HHS, the National Institutes of Health (NIH) is the primary U.S. federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. Within NIH, the National Institute of Allergy and Infectious Diseases conducts and supports research — throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
作为 HHS 的一部分，美国国立卫生研究院（NIH）是美国联邦政府开展和支持基础、临床和转化医学研究的主要机构，目前正在研究常见病和罕见病的病因、治疗和治愈方法。在美国国立卫生研究院内，国家过敏和传染病研究所在全美和全球范围内开展并支持研究工作，研究传染病和免疫介导疾病的病因，并开发预防、诊断和治疗这些疾病的更好方法。新闻稿、概况介绍和其他与 NIAID 相关的资料可在 NIAID 网站上查阅。
About Wellcome 关于惠康
Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health.
惠康支持科学解决每个人面临的紧迫健康挑战。我们支持对生命、健康和福祉的探索研究，我们正在应对三大全球性健康挑战：心理健康、传染病以及气候与健康。
About the German Federal Ministry of Education and Research (BMBF)
关于德国联邦教育与研究部 (BMBF)
Education and research are crucial foundations for our future. Thus, the promotion of education, science and research is a policy priority of the German Federal Government. The German Federal Ministry of Education and Research (BMBF) strengthens education at all stages of life and provides support for scientific research and innovation.
教育和研究是我们未来的重要基础。因此，促进教育、科学和研究是德国联邦政府的优先政策。德国联邦教育与研究部（BMBF）加强人生各个阶段的教育，并为科学研究和创新提供支持。